MEI Pharma Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jay File
Chief executive officer
US$614.7k
Total compensation
| CEO salary percentage | 73.2% |
| CEO tenure | 1.3yrs |
| CEO ownership | n/a |
| Management average tenure | 2.2yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 17
Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)
Dec 30Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)
Nov 19We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely
May 18Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022
Mar 26Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts
Feb 12MEI Pharma: Another PI3K Delta Progressing To The FDA
Feb 01Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates
Dec 02We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate
Nov 04MEI Pharma EPS misses by $0.12, misses on revenue
May 06MEI Pharma promotes Richard Ghalie to chief medical officer
Apr 30MEI Pharma shares rise 4% as Wells Fargo says voruciclib undervalued
Apr 26The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 11
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$47m |
| Jun 30 2024 | US$615k | US$450k | US$18m |
Compensation vs Market: Jay's total compensation ($USD614.70K) is about average for companies of similar size in the US market ($USD651.40K).
Compensation vs Earnings: Insufficient data to compare Jay's compensation with company performance.
CEO
Jay File (54 yo)
1.3yrs
Tenure
US$614,700
Compensation
Mr. Justin J. File, also known as Jay, serves as CFO & Corporate Secretary at MEI Pharma, Inc. since August 01, 2023 and serves as its Acting Chief Executive Officer from August 01, 2024. He had been an Ex...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO | 1.3yrs | US$614.70k | no data | |
| Senior Vice President of Operations & Quality | 1.4yrs | no data | no data | |
| Vice President of Legal Affairs | 1.9yrs | no data | no data | |
| Chief People Officer | 2.5yrs | no data | no data | |
| Strategic Advisor | 13.5yrs | US$755.98k | no data | |
| Senior Vice President of Corporate Affairs | 3.6yrs | no data | no data |
2.2yrs
Average Tenure
Experienced Management: MEIP's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairperson | 6.8yrs | US$117.20k | 0.028% $ 4.4k | |
| Independent Non-Executive Director | 11.5yrs | US$122.78k | 0% $ 0 | |
| Independent Non-Executive Director | 11.8yrs | US$115.28k | 0.0075% $ 1.2k | |
| Independent Non-Executive Director | 1.2yrs | US$112.40k | 0.14% $ 22.1k | |
| Independent Director | 1.1yrs | US$114.07k | 0.12% $ 18.6k | |
| Director | 1.1yrs | US$68.06k | no data |
4.0yrs
Average Tenure
49yo
Average Age
Experienced Board: MEIP's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 11:03 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MEI Pharma, Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephen V. Byrne | BofA Global Research |
| Jonathan Aschoff | Brean Capital |
| Gene Mack | Brean Capital |